alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 9,526–9,550 of 27,380 studies, newest first · page 382 of 1096.

December 2021 25

  1. 2021-12-08

    Exercise plasma boosts memory and dampens brain inflammation via clusterin

    ✓ Peer-reviewed Genetics Nature

    Key finding: Plasma proteomic analysis revealed a concerted increase in complement cascade inhibitors including clusterin (CLU). +1 more finding

    Full summary, score breakdown and related studies → Original source

  2. 2021-12-08

    Structure of pathological TDP-43 filaments from ALS with FTLD

    ✓ Peer-reviewed Lewy body dementia Nature

    Key finding: An abundance of glycine and neutral polar residues facilitates numerous turns and restricts β-strand length, which results in an absence of β-sheet stacking that is associated with cross-β amyloid structure.

    Full summary, score breakdown and related studies → Original source

  3. 2021-12-08

    Novel SNX13 Frameshift Variant in an Individual with Developmental Delay

    ✓ Peer-reviewed Down syndrome and Alzheimer's Cytogenetic and genome research

    Key finding: Recently, an increasing number of genes have been associated with global developmental delay (GDD) and intellectual disability (ID). +4 more findings

    Full summary, score breakdown and related studies → Original source

  4. 2021-12-07

    Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial

    ✓ Peer-reviewed Clinical trials Clinical nutrition (Edinburgh, Scotland)

    Key finding: Following 24-month supplementation, individuals in the active group (n = 30; aged 69.03 ± 4.41 years; 56.7% female) recorded significantly fewer errors in working memory tasks than individuals receiving placebo (n = 30; aged 69.77 ± 3.74 years; 70% female) (point estimate effect sizes ranged 0.090-0.105). +4 more findings

    Full summary, score breakdown and related studies → Original source

  5. 2021-12-07

    Normal cerebrospinal fluid concentrations of PDGFRβ in patients with cerebral amyloid angiopathy and Alzheimer's disease

    ✓ Peer-reviewed Tau biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: PDGFRβ levels were similar in CAA patients and controls (P = .78) and in aMCI/AD clinical phenotype and controls (P = .91). aMCI/AD patients with an AD+ biomarker profile (A+T+[N+]) had increased PDGFRβ levels compared to (A-T-[N-]) controls (P = .006). +1 more finding

    Full summary, score breakdown and related studies → Original source

  6. 2021-12-07

    Periodontal Disease: The Good, The Bad, and The Unknown

    ✓ Peer-reviewed Disease mechanisms Frontiers in cellular and infection microbiology

    Key finding: However, recent studies have revealed the importance of previously unidentified microbes involved in disease progression, including various viruses, phages and bacterial species. +1 more finding

    Full summary, score breakdown and related studies → Original source

  7. 2021-12-07

    Locus coeruleus integrity is related to tau burden and memory loss in autosomal-dominant Alzheimer's disease

    ✓ Peer-reviewed Brain scans and imaging Neurobiology of aging

    Key finding: Using high-resolution MRI and tau PET, we found lower rostral LC integrity in symptomatic participants. +2 more findings

    Full summary, score breakdown and related studies → Original source

  8. 2021-12-07

    rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data

    ✓ Peer-reviewed Long-term cohort studies NeuroImage

    Key finding: Here we describe rPOP (robust PET-Only Processing), a MATLAB-based MRI-free pipeline implementing non-linear warping and differential smoothing of amyloid-PET scans performed with any of the FDA-approved radiotracers ( 18 F-florbetapir/FBP, 18 F-florbetaben/FBB or 18 F-flutemetamol/FLUTE). +3 more findings

    Full summary, score breakdown and related studies → Original source

  9. 2021-12-06

    Endophenotype-based in silico network medicine discovery combined with insurance record data mining identifies sildenafil as a candidate drug for Alzheimer's disease

    ✓ Peer-reviewed Drug development Nature aging

    Key finding: Based on retrospective case-control pharmacoepidemiologic analyses of insurance claims data for 7.23 million individuals, we found that sildenafil usage was significantly associated with a 69% reduced risk of AD (hazard ratio = 0.31, 95% confidence interval 0.25-0.39, P<1.0×10 -8 ). +1 more finding

    Full summary, score breakdown and related studies → Original source

  10. 2021-12-06

    Alzheimer's disease biomarkers in Black and non-Hispanic White cohorts: A contextualized review of the evidence

    ✓ Peer-reviewed Disparities Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: In this review, we summarize current data, comparing the few studies presenting these findings. +2 more findings

    Full summary, score breakdown and related studies → Original source

  11. 2021-12-06

    Alzheimer disease in African American individuals: increased incidence or not enough data?

    ✓ Peer-reviewed Disparities Nature reviews. Neurology

    Key finding: Older African American individuals bear a disproportionate burden of AD and cognitive impairment compared with non-Latino white individuals.

    Full summary, score breakdown and related studies → Original source

  12. 2021-12-05

    Alpha desynchronization during Stroop test unmasks cognitively healthy individuals with abnormal CSF Amyloid/Tau

    ✓ Peer-reviewed Tau biomarkers Neurobiology of aging

    Key finding: We used quantitative electroencephalography combined with Stroop testing to identify changes of inhibitory controls in cognitively healthy individuals with an abnormal versus normal ratio of cerebrospinal fluid (CSF) amyloid/total-tau. +3 more findings

    Full summary, score breakdown and related studies → Original source

  13. 2021-12-04

    Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression

    ✓ Peer-reviewed Drug development International journal of molecular sciences

    Key finding: In this study, we found that microRNA-485-3p (miR-485-3p) was overexpressed in the brain tissues, cerebrospinal fluid, and plasma of patients with AD, and its antisense oligonucleotide (ASO) reduced Aβ plaque accumulation, tau pathology development, neuroinflammation, and cognitive decline in a transgenic mouse model of AD. +1 more finding

    Full summary, score breakdown and related studies → Original source

  14. 2021-12-04

    Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231

    ✓ Peer-reviewed Biomarkers Alzheimer's research & therapy

    Key finding: P-tau isoforms can be measured robustly by several novel high-sensitive Simoa assays. +1 more finding

    Full summary, score breakdown and related studies → Original source

  15. 2021-12-03

    EGb 761® Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer's Dementia-Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial

    ✓ Peer-reviewed Clinical trials Healthcare (Basel, Switzerland)

    Key finding: Concomitant intake of acetylsalicylic acid was documented for 68 patients in the placebo group and 105 in the EGb 761® groups. +4 more findings

    Full summary, score breakdown and related studies → Original source

  16. 2021-12-03

    Blood-based biomarkers for Alzheimer's disease

    ✓ Peer-reviewed Biomarkers EMBO molecular medicine

    Key finding: As a result of rapid advances in the development of ultra-sensitive assays, the levels of pathological brain- and AD-related proteins can now be measured in blood, with recent work showing promising results.

    Full summary, score breakdown and related studies → Original source

  17. 2021-12-03

    White matter hyperintensities are associated with grey matter atrophy and cognitive decline in Alzheimer's disease and frontotemporal dementia

    ✓ Peer-reviewed Long-term cohort studies Neurobiology of aging

    Key finding: We compared the impact of WMHs on grey matter (GM) atrophy and cognition in normal aging (n = 571), mild cognitive impairment (MCI, n = 551), Alzheimer's dementia (AD, n = 212), fronto-temporal dementia (FTD, n = 125), and Parkinson's disease (PD, n = 271). +3 more findings

    Full summary, score breakdown and related studies → Original source

  18. 2021-12-02

    Distinct characteristics of limbic-predominant age-related TDP-43 encephalopathy in Lewy body disease

    ✓ Peer-reviewed Brain tissue and pathology Acta neuropathologica

    Key finding: Demographic analysis showed LATE associated with age in all four cohorts and the frequency of LATE was the highest in LBD + AD followed by AD, LBD, and Aging. +3 more findings

    Full summary, score breakdown and related studies → Original source

  19. 2021-12-02

    Risk of overactive bladder associated with cholinesterase inhibitors in dementia

    ✓ Peer-reviewed Treatments Journal of the American Geriatrics Society

    Key finding: The study included 524,975 older adults with dementia who were incident users of ChEIs (donepezil 80.72%, rivastigmine 16.41%, galantamine 2.87%). +4 more findings

    Full summary, score breakdown and related studies → Original source

  20. 2021-12-02

    Multi-Omics Analysis of Microglial Extracellular Vesicles From Human Alzheimer's Disease Brain Tissue Reveals Disease-Associated Signatures

    ✓ Peer-reviewed TREM2 and immune genetics Frontiers in pharmacology

    Key finding: Extracellular vesicles (EVs) are lipid bilayer-delimited particles that are released from almost all types of cell. +3 more findings

    Full summary, score breakdown and related studies → Original source

  21. 2021-12-02

    Black and White individuals differ in dementia prevalence, risk factors, and symptomatic presentation

    ✓ Peer-reviewed Disparities Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: Despite lower dementia prevalence, Black participants with dementia had more dementia risk factors, as well as greater cognitive impairment and neuropsychiatric symptom severity than White participants.

    Full summary, score breakdown and related studies → Original source

  22. 2021-12-02

    Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study

    ✓ Peer-reviewed Treatments Cognitive and behavioral neurology : official journal of the Society for Behavioral and Cognitive Neurology

    Key finding: The two groups' baseline characteristics, including age, sex, mean length of education, and disease duration, were comparable, as were their baseline Mini-Mental State Examination scores.

    Full summary, score breakdown and related studies → Original source

  23. 2021-12-02

    Dose-response association between device-measured physical activity and incident dementia: a prospective study from UK Biobank

    ✓ Peer-reviewed Prevention and risk BMC Medicine

    Key finding: After a median follow-up of 6.3 years, 678 individuals were diagnosed with dementia. +3 more findings

    Full summary, score breakdown and related studies → Original source

  24. 2021-12-01

    Consensus Statement Regarding the Application of Biogen to Health Canada for Approval of Aducanumab

    ✓ Peer-reviewed Treatments Canadian Geriatrics Journal

    Key finding: A similar application for approval has been submitted to Health Canada. +4 more findings

    Full summary, score breakdown and related studies → Original source

  25. 2021-12-01

    Evaluation of liraglutide in the treatment of Alzheimer's disease

    ✓ Peer-reviewed Drug development Alzheimer s & Dementia

    Key finding: Preclinical evidence in transgenic models of Alzheimer’s disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. +3 more findings

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →